Kerry reported third-quarter volume growth of 4.1% on 22 October, as food manufacturers’ demand for reformulation supported the ingredient supplier’s performance. Pricing returned to modest growth during the quarter, making the update relevant to buyers planning new products and reviewing ingredient costs.

The Irish group’s nine-month volumes increased 3.6%, while pricing fell 0.6%. Third-quarter pricing was positive at 0.2%. Its year-to-date EBITDA margin improved by 50 basis points, or half a percentage point, mainly through its Accelerate 2.0 efficiency programme.

Reported nine-month revenue nevertheless declined 0.6%, reflecting currency movements and changes to the business portfolio as well as trading. That distinction matters: a fall in reported revenue does not mean customers bought fewer ingredients.

Kerry, part of the Irish food manufacturing supply base, identified snacks, meat, dairy and beverages as growth areas. Its technologies include salt and sugar reduction, protein taste management and preservation.

For category teams, reformulation creates a different buying decision from a simple ingredient substitution. Reducing sugar or changing protein sources can affect flavour, texture and processing. A cheaper specification has limited commercial value if it adds production losses or weakens repeat purchase.

Procurement teams should therefore compare the cost of the finished product, including dosage, factory trials, waste and shelf-life validation. Kerry’s group pricing figures provide context for negotiations, but they do not establish the price movement for any individual ingredient or customer contract.

The regional picture also varies. Kerry’s results presentation shows Q3 volume growth of 4.6% in the Americas, 1.3% in Europe and 5.7% across Asia Pacific, the Middle East and Africa. European buyers should avoid treating the global headline as a direct measure of local demand.

For UK supermarket suppliers developing revised recipes, the practical issue is whether technical support and manufacturing capacity are available when a retailer’s range change requires them. Agreeing trial volumes, approval stages and implementation dates early can reduce disruption during the switch.

Kerry maintained its forecast for 6%–10% growth in constant-currency adjusted earnings per share in 2026. Buyers will be watching whether the return to positive pricing continues and how the company’s reformulation pipeline translates into product launches.

Editor’s note: Information is based on Kerry Group’s Q3 interim management statement and results presentation, published on 22 October 2026. GTN added analysis of recipe changes, procurement costs and implementation risks.